FDA clears CTA313 trial: off-the-shelf CAR T-cell therapy for progressive multiple sclerosis (June 2026)
On June 9, 2026, the US FDA cleared an Investigational New Drug application from Imviva Biotech for CTA313 — an allogeneic ("off-the-shelf") dual-targeted CD19/BCMA CAR T-cell therapy — to begin a Phase 1b basket trial in progressive MS, systemic lupus erythematosus and autoimmune encephalitis. Here is exactly what this means, what CAR T-cell therapy is, why the "off-the-shelf" design matters, what the early Chinese lupus data show, and what people with progressive MS should realistically expect.
What actually happened
In conversations with people in the MS community, this is one of the questions that keeps coming back. On June 9, 2026, biotechnology company [Imviva Biotech](https://www.imvivabio.com/) announced that the US Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for CTA313, an investigational off-the-shelf CAR T-cell therapy. The clearance allows the company to begin a Phase 1b basket clinical trial in three B-cell-driven autoimmune diseases: progressive multiple sclerosis, systemic lupus erythematosus (SLE) and autoimmune encephalitis. The announcement was reported by [Multiple Sclerosis News Today](https://multiplesclerosisnewstoday.com/news-posts/2026/06/12/fda-clears-cta313-trial-progressive-ms-autoimmune-diseases/) on June 12, 2026 and confirmed in the [official Imviva press release on GlobeNewswire](https://www.globenewswire.com/news-release/2026/06/09/3308823/0/en/imviva-biotech-receives-fda-investigational-new-drug-approval-for-cta313-a-dual-targeted-cd19-bcma-allogeneic-car-t-cell-therapy-for-autoimmune-diseases.html).
What is CAR T-cell therapy — in one paragraph
CAR T-cell therapy takes immune T-cells and re-engineers them in the laboratory to display a Chimeric Antigen Receptor (CAR) — a synthetic receptor that recognises a specific protein on a target cell. Once infused back into the patient, these engineered T-cells hunt down and destroy every cell carrying that protein. The approach is already FDA-approved for several blood cancers (Kymriah, Yescarta, Breyanzi, Carvykti, Abecma, and others), and is now being intensively tested in autoimmune diseases — where the goal is to wipe out the abnormal B-cells that drive the autoimmune attack, and give the immune system a chance to "reset".
Why B-cells matter in progressive MS
Multiple sclerosis was once considered a purely T-cell disease. In the last decade, evidence has shifted decisively: B-cells are central drivers of both relapsing and progressive MS. This is exactly why [Ocrevus (ocrelizumab)](/en/blog/ocrevus-ocrelizumab-complete-2026-guide-works-efficacy-safety-access-ms) and [Kesimpta (ofatumumab)](/en/blog/kesimpta-ofatumumab-complete-2026-guide-works-efficacy-self-injection-ms) — both anti-CD20 antibodies that deplete B-cells — became blockbuster MS therapies, and why Ocrevus remains the only DMT specifically approved for primary progressive MS. But even the best anti-CD20 antibody does not reach every B-cell compartment, especially not the long-lived plasma cells and B-cells in the brain and meninges that drive smouldering, progressive disease. A CAR T-cell therapy can potentially go where antibodies cannot.
What makes CTA313 different — CD19 + BCMA, together
Most CAR T-cell therapies for autoimmune disease target a single B-cell protein — usually CD19. CTA313 is engineered to simultaneously target two B-cell proteins:
- CD19 — found on virtually all B-cells from the pro-B stage through most of maturation.
- BCMA (B-cell maturation antigen) — found on plasma cells and long-lived antibody-producing cells that CD19-only therapies often miss.
By targeting both, CTA313 is designed to achieve a deeper and more durable depletion of the entire B-cell lineage, including the long-lived autoantibody-producing plasma cells that traditional therapies struggle to reach. In principle this could translate into a longer-lasting immune "reset" — which is exactly what progressive MS most needs.
Why "off-the-shelf" is a big deal
Traditional CAR T-cell therapies are autologous — made individually from each patient's own T-cells. The process requires apheresis (a blood-drawing procedure similar to plasmapheresis to collect T-cells), shipping the cells to a manufacturing facility, weeks of engineering and expansion, and then infusing them back. For someone with a rapidly progressing autoimmune disease, those weeks are dangerous — and the cost per patient runs into hundreds of thousands of dollars.
CTA313 is allogeneic — made from healthy donor T-cells that are genetically modified once and then stored in vials, ready to use. This "off-the-shelf" model has three advantages:
- Speed — a patient can potentially receive the therapy in days instead of weeks.
- No apheresis — no need to collect the patient's own T-cells, which is a real burden for people already fatigued or physically disabled by MS.
- Scale and cost — one manufacturing batch can treat many patients, opening the door to broader access in the future.
The tradeoff is that donor T-cells can be rejected by the recipient's immune system. Imviva says CTA313 was engineered on its proprietary ANSWER platform, which adds extra genetic modifications intended to help the donor cells evade immune rejection and stay active long enough to work.
What is a "basket" trial?
A basket trial tests one therapy across several different diseases that share a common biological mechanism — in this case, a B-cell-driven autoimmune process. The Phase 1b CTA313 study will enrol people with:
Progressive multiple sclerosis — both primary progressive and secondary progressive forms are B-cell driven and remain the biggest unmet need in MS. Systemic lupus erythematosus (SLE) — a classic B-cell autoimmune disease. Autoimmune encephalitis — a rare condition where the immune system attacks the brain directly, causing inflammation, seizures and cognitive change.
The trial will evaluate safety, efficacy and cellular pharmacokinetics (how long the CAR T-cells survive in the body) across all three arms. The design lets researchers spot early safety and efficacy signals across conditions and then move the strongest indications into Phase 2 more quickly.
Early evidence: what the Chinese lupus data show
CTA313 is not brand-new — it is already being tested in an open-label Phase 1/2 trial in China for systemic lupus erythematosus and lupus nephritis. Results presented in early June 2026 ([Imviva ASCO 2026 abstract](https://www.imvivabio.com/uploads/files/202606/63e0f094b8058fc191ab36f70b21fa2d.pdf)) reported:
- 50% of evaluable patients achieved remission at 1 year after a single infusion.
- 75% reached a low disease activity state at 1 year.
- Deep B-cell depletion with sustained reductions in disease-associated autoantibodies.
- Anti-dsDNA autoantibodies remained undetectable up to one year, even after B-cells recovered — a signal that the therapy may achieve a genuine immune "reset" rather than just temporary suppression.
These are lupus data — not MS data — but they are the strongest evidence to date that CTA313 can produce a durable B-cell depletion and clinically meaningful outcomes in a B-cell autoimmune disease.
Is CAR T-cell therapy already being tested in MS?
Yes. Since 2024–2025, several CAR T-cell programs have entered early MS trials worldwide, including work by Kyverna, Cabaletta Bio, Bristol Myers Squibb and others. Early case reports in progressive MS have shown profound B-cell depletion, disappearance of oligoclonal bands in cerebrospinal fluid, and clinical stabilisation in a small number of patients. The field is moving fast, but every reported case so far has been an autologous CAR T given at a specialist centre. CTA313 is one of the first allogeneic (off-the-shelf) CAR T therapies to enter formal FDA-cleared testing in progressive MS specifically. See our related coverage of [CAR T-cell therapy in MS](/en/blog/car-t-cell-therapy-multiple-sclerosis) for background.
What are the risks?
CAR T-cell therapy is powerful but not without cost. In cancer, the well-known risks are cytokine release syndrome (CRS), neurotoxicity (ICANS), prolonged B-cell aplasia (which raises infection risk), and rare cases of secondary malignancies from the gene-editing process. Autoimmune CAR T trials so far have reported milder and less frequent CRS than cancer trials, likely because the tumour burden of abnormal cells is much smaller. But long-term safety is still being learned. For an allogeneic product like CTA313, the additional theoretical risk is immune rejection of donor cells — which is exactly what the ANSWER platform modifications are designed to prevent.
What should a person with progressive MS do today?
- Do not stop your current DMT. No CAR T therapy is yet approved for MS. Proven DMTs like [Ocrevus](/en/blog/ocrevus-ocrelizumab-complete-2026-guide-works-efficacy-safety-access-ms), [Kesimpta](/en/blog/kesimpta-ofatumumab-complete-2026-guide-works-efficacy-self-injection-ms), [Tysabri](/en/blog/tysabri-natalizumab-complete-2026-guide-works-affirm-efficacy-pml-risk-ms) and [Mavenclad](/en/blog/mavenclad-cladribine-complete-2026-guide-short-oral-course-long-term-ms) remain the standard of care for now.
- Ask your neurologist about clinical trials. The CTA313 Phase 1b trial and other CAR T MS trials are actively recruiting at specialist centres. Enrolment criteria are strict — usually active progressive disease with limited remaining DMT options.
- Follow reliable sources. Read updates from your national MS society, [ClinicalTrials.gov](https://clinicaltrials.gov/), and centres running the trials. Avoid unverified claims on social media.
- Manage the fundamentals. Vitamin D, aerobic exercise, sleep, smoking cessation and mental health support ([our mental health guide](/en/blog/mental-health-ms-new-2026-guidelines)) still matter more day-to-day than any experimental therapy.
This is genuinely important news. CTA313 is the first dual-targeted CD19/BCMA allogeneic CAR T-cell therapy to receive FDA clearance for a basket trial that includes progressive multiple sclerosis — a form of MS with the fewest treatment options. The combination of an off-the-shelf design, deeper B-cell depletion via dual targeting, and encouraging early lupus data makes this one of the most watched autoimmune CAR T programs of 2026. But it is a Phase 1b trial — the earliest stage of human testing. A licensed treatment for progressive MS from this program, if it works, is still many years away. Realistic hope, not premature celebration, is the right response.
Sources and citations
Primary FDA and company documents
- Imviva Biotech. *Imviva Biotech Receives FDA Investigational New Drug Approval for CTA313, a Dual-Targeted CD19/BCMA Allogeneic CAR T-Cell Therapy for Autoimmune Diseases.* Official press release, GlobeNewswire, June 9, 2026. [Full release](https://www.globenewswire.com/news-release/2026/06/09/3308823/0/en/imviva-biotech-receives-fda-investigational-new-drug-approval-for-cta313-a-dual-targeted-cd19-bcma-allogeneic-car-t-cell-therapy-for-autoimmune-diseases.html)
- US Food and Drug Administration. *Investigational New Drug (IND) Application — regulatory background.* [FDA.gov IND overview](https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application)
- Imviva Biotech. *CTA313 program page and ANSWER allogeneic platform (dual CD19/BCMA CAR, TCR/HLA-I/HLA-II edits for immune evasion).* [imvivabio.com/science](https://www.imvivabio.com/science.html#Platform)
- Imviva Biotech. *CTA313 pipeline overview — indications, Phase 1b basket design.* [imvivabio.com/pipeline](https://www.imvivabio.com/pipeline.html)
Key clinical trial data cited in this article
- Imviva Biotech. *CTA313 in refractory SLE and lupus nephritis — Phase 1/2 open-label China study (NCT number pending).* ASCO 2026 poster abstract, June 2026. Reported: 50% remission and 75% low disease activity state at 12 months after a single infusion; sustained anti-dsDNA autoantibody suppression up to 1 year despite B-cell recovery. [Full abstract PDF](https://www.imvivabio.com/uploads/files/202606/63e0f094b8058fc191ab36f70b21fa2d.pdf)
- ClinicalTrials.gov. *Search: CTA313 or Imviva* — for the upcoming US Phase 1b basket trial in progressive MS, SLE and autoimmune encephalitis (registration pending post-IND clearance). [clinicaltrials.gov](https://clinicaltrials.gov/search?term=CTA313)
Independent news coverage
- Inacio P. *FDA clears CTA313 trial for progressive MS, autoimmune diseases.* Multiple Sclerosis News Today, June 12, 2026. [Article](https://multiplesclerosisnewstoday.com/news-posts/2026/06/12/fda-clears-cta313-trial-progressive-ms-autoimmune-diseases/)
- Endpoints News / FierceBiotech coverage of allogeneic CAR-T in autoimmune disease (2025–2026 landscape).
Peer-reviewed CAR-T in autoimmunity (background evidence)
- Müller F, Taubmann J, Bucci L, et al. *CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up.* N Engl J Med. 2024;390:687–700. [DOI: 10.1056/NEJMoa2308917](https://doi.org/10.1056/NEJMoa2308917)
- Fischbach F, Richter J, Pfeffer LK, et al. *CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis.* Med (Cell Press). 2024;5(6):550–558.e2. [DOI: 10.1016/j.medj.2024.03.002](https://doi.org/10.1016/j.medj.2024.03.002)
- Mackensen A, Müller F, Mougiakakos D, et al. *Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.* Nat Med. 2022;28:2124–2132. [DOI: 10.1038/s41591-022-02017-5](https://doi.org/10.1038/s41591-022-02017-5)
- Krishnan A, Bhatia S, et al. *Dual-targeted CD19/BCMA CAR-T for B-cell malignancies — rationale for autoimmunity.* Blood Cancer J, 2023.
- Depil S, Duchateau P, Grupp SA, et al. *"Off-the-shelf" allogeneic CAR T cells: development and challenges.* Nat Rev Drug Discov. 2020;19(3):185–199. [DOI: 10.1038/s41573-019-0051-2](https://doi.org/10.1038/s41573-019-0051-2)
MS pathophysiology (B-cell rationale)
- Hauser SL, Cree BAC. *Treatment of Multiple Sclerosis: A Review.* Am J Med. 2020;133(12):1380–1390.e2. [DOI: 10.1016/j.amjmed.2020.05.049](https://doi.org/10.1016/j.amjmed.2020.05.049)
- Montalban X, Hauser SL, Kappos L, et al. *Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (ORATORIO).* N Engl J Med. 2017;376:209–220. [DOI: 10.1056/NEJMoa1606468](https://doi.org/10.1056/NEJMoa1606468)
*All links accessed July 2026. This article is educational and does not replace medical advice — consult your neurologist for personalised recommendations.*